ACADIA Pharmaceuticals EVP Sells 6,950 Shares

Insider transaction represents a 47.74% decrease in their position

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Executive Vice President Jennifer Rhodes sold 6,950 shares of the company's stock on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the sale, Rhodes now directly owns 7,609 shares in the company, valued at $177,898.42.

Why it matters

Insider transactions, such as this sale by an ACADIA Pharmaceuticals executive, can provide insights into a company's performance and future outlook from the perspective of those closest to the business. This particular sale represents a significant reduction in the executive's position, which may signal a potential shift in sentiment or strategy at the company.

The details

The transaction involved the sale of 6,950 shares by ACADIA Pharmaceuticals EVP Jennifer Rhodes. The shares were sold at an average price of $23.38, resulting in a total transaction value of $162,491.00. Following the sale, Rhodes now directly owns 7,609 shares in the company, valued at $177,898.42. This sale represents a 47.74% decrease in the executive's position.

  • The transaction occurred on Monday, February 9th, 2026.

The players

Jennifer Rhodes

Executive Vice President of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by an ACADIA Pharmaceuticals executive could signal a potential shift in sentiment or strategy at the company, as the transaction represents a significant reduction in the executive's position. Investors may want to closely monitor the company's performance and any further insider transactions for additional insights into the company's outlook.